To determine whether patients aged 75 years and older with non-rheumatic atrial fibrillation should be treated with aspirin or warfarin.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Warfarin (Coumadin®)Drug
Intervention Desc: Anticoagulant (Vitamin K antagonist)
Primary care based randomized, controlled trial.
Eligible patients with atrial fibrillation are randomised to adjusted dose warfarin (target INR 2.5, range 2-3) or aspirin (75mg). Patients are followed up after the first 3 months, then every 6 months for an average of 3 years.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Fatal or non-fatal disabling stroke (ischemic or hemorrhagic), other intra-cranial hemorrhage, or significant arterial embolism.|
|Secondary||Major extra-cranial hemorrhage, death (all cause, vascular), hospital admissions (all cause, vascular), cognition, quality of life, disability and compliance with study medication.|